Rankings
▼
Calendar
TEVA Q2 2025 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena
TEVA
Teva Pharmaceutical Industries Limited
$37B
Q2 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$4.2B
+0.3% YoY
Gross Profit
$2.1B
50.3% margin
Operating Income
$455M
10.9% margin
Net Income
$282M
6.8% margin
EPS (Diluted)
$0.24
QoQ Revenue Growth
+7.3%
Cash Flow
Operating Cash Flow
$227M
Free Cash Flow
$131M
Stock-Based Comp.
$38M
Balance Sheet
Total Assets
$40.1B
Total Liabilities
$33.3B
Stockholders' Equity
$6.8B
Cash & Equivalents
$2.2B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4.2B
$4.2B
+0.3%
Gross Profit
$2.1B
$2.0B
+3.9%
Operating Income
$455M
-$5M
+9200.0%
Net Income
$282M
-$846M
+133.3%
Revenue Segments
Product
$3.6B
87%
Distribution Service
$377M
9%
Product and Service, Other
$117M
3%
License
$46M
1%
Geographic Segments
United States Segment
$2.2B
55%
Europe Segment
$1.3B
33%
International Markets
$495M
13%
← FY 2025
All Quarters
Q3 2025 →